Neves Cardoso Pedro, Pinheiro Ana Fernanda, Meira Jorge, Pedrosa Ana Catarina, Falcão Manuel S, Pinheiro-Costa João, Falcão-Reis Fernando, Carneiro Ângela M
Department of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, Portugal.
Faculty of Medicine, University of Porto, Porto, Portugal.
J Ophthalmol. 2017;2017:6835782. doi: 10.1155/2017/6835782. Epub 2017 Oct 19.
To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD.
Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up.
164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, < 0.005) between the first and third year.
Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved.
报告年龄相关性黄斑变性（AMD）患者从玻璃体内注射贝伐单抗或雷珠单抗转换为阿柏西普治疗后的长期临床结果。
回顾性分析随访1年、2年和3年后最佳矫正视力（BCVA）、频域光学相干断层扫描（SD-OCT）图像及注射频率的变化。
共分析164只眼，其中101只眼从贝伐单抗转换（第1组），63只眼从雷珠单抗转换（第2组）。转换后1年，BCVA平均总体下降2个早期糖尿病性视网膜病变研究（ETDRS）字母，差异无统计学意义。3年后，BCVA平均总体下降7个ETDRS字母，具有统计学意义。在1年、2年和3年时，中心视网膜厚度（CRT）均值有显著改善。第1年和第3年之间，每年平均注射次数显著减少（从7.8次降至6.5次，P<0.005）。
阿柏西普可用于治疗难治性新生血管性AMD，具有良好的形态学反应。然而，从长期来看，未实现BCVA稳定。
